Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
Identifieur interne : 003B32 ( Main/Exploration ); précédent : 003B31; suivant : 003B33Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
Auteurs : Jens H. Kuhn [États-Unis, Allemagne] ; WENHUI LI [États-Unis] ; Sheli R. Radoshitzky [États-Unis] ; Hyeryun Choe [États-Unis] ; Michael Farzan [États-Unis]Source :
- Antiviral therapy : (London) [ 1359-6535 ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Bovins, Chats, Chiens, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (), Glycoprotéines membranaires (métabolisme), Humains, Lapins, Modèles moléculaires, Peptidyl-Dipeptidase A (), Peptidyl-Dipeptidase A (métabolisme), Protéines de l'enveloppe virale (), Protéines de l'enveloppe virale (métabolisme), Rats, Récepteurs viraux (), Récepteurs viraux (métabolisme), Syndrome respiratoire aigu sévère (traitement médicamenteux), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (), Virus du SRAS (pathogénicité).
- MESH :
- métabolisme : Glycoprotéines membranaires, Peptidyl-Dipeptidase A, Protéines de l'enveloppe virale, Récepteurs viraux.
- pathogénicité : Virus du SRAS.
- pharmacologie : Antiviraux.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Pascal (Inist)
- Animaux, Bovins, Chats, Chiens, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Humains, Lapins, Modèles moléculaires, Peptidyl-Dipeptidase A, Protéines de l'enveloppe virale, Rats, Récepteurs viraux, Syndrome respiratoire aigu sévère, Coronavirus, Traitement, Antiviral, Thérapeutique ciblée, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiviral, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Cats, Cattle, Coronavirus, Dogs, Humans, Membrane Glycoproteins (chemistry), Membrane Glycoproteins (drug effects), Membrane Glycoproteins (metabolism), Models, Molecular, Peptidyl-Dipeptidase A (drug effects), Peptidyl-Dipeptidase A (metabolism), Rabbits, Rats, Receptors, Virus (drug effects), Receptors, Virus (metabolism), SARS Virus (drug effects), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (virology), Severe acute respiratory syndrome, Spike Glycoprotein, Coronavirus, Targeted therapy, Treatment, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (drug effects), Viral Envelope Proteins (metabolism).
- MESH :
- chemical , chemistry : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , drug effects : Membrane Glycoproteins, Peptidyl-Dipeptidase A, Receptors, Virus, Viral Envelope Proteins.
- chemical , metabolism : Membrane Glycoproteins, Peptidyl-Dipeptidase A, Receptors, Virus, Viral Envelope Proteins.
- chemical , pharmacology : Antiviral Agents.
- chemical , therapeutic use : Antiviral Agents.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- pathogenicity : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Cats, Cattle, Dogs, Humans, Models, Molecular, Rabbits, Rats, Spike Glycoprotein, Coronavirus.
Abstract
The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000351
- to stream PascalFrancis, to step Curation: 000638
- to stream PascalFrancis, to step Checkpoint: 000341
- to stream Main, to step Merge: 003C88
- to stream PubMed, to step Corpus: 001C98
- to stream PubMed, to step Curation: 001C98
- to stream PubMed, to step Checkpoint: 001C95
- to stream Ncbi, to step Merge: 001A92
- to stream Ncbi, to step Curation: 001A92
- to stream Ncbi, to step Checkpoint: 001A92
- to stream Main, to step Merge: 003715
- to stream Main, to step Curation: 003B32
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title><author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1><s2>Berlin</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">07-0427335</idno><date when="2007">2007</date><idno type="stanalyst">PASCAL 07-0427335 INIST</idno><idno type="RBID">Pascal:07-0427335</idno><idno type="wicri:Area/PascalFrancis/Corpus">000351</idno><idno type="wicri:Area/PascalFrancis/Curation">000638</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000341</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000341</idno><idno type="wicri:doubleKey">1359-6535:2007:Kuhn J:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">003C88</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17944271</idno><idno type="wicri:Area/PubMed/Corpus">001C98</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C98</idno><idno type="wicri:Area/PubMed/Curation">001C98</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C98</idno><idno type="wicri:Area/PubMed/Checkpoint">001C95</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C95</idno><idno type="wicri:Area/Ncbi/Merge">001A92</idno><idno type="wicri:Area/Ncbi/Curation">001A92</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A92</idno><idno type="wicri:doubleKey">1359-6535:2007:Kuhn J:severe:acute:respiratory</idno><idno type="wicri:Area/Main/Merge">003715</idno><idno type="wicri:Area/Main/Curation">003B32</idno><idno type="wicri:Area/Main/Exploration">003B32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies</title><author><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Biology, Chemistry, Pharmacy, Freie Universität Berlin</s1><s2>Berlin</s2><s3>DEU</s3><sZ>1 aut.</sZ></inist:fA14><country>Allemagne</country><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Pediatrics, Children's Hospital, Harvard Medical School</s1><s2>Boston, MA</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center</s1><s2>Southborough, MA</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><series><title level="j" type="main">Antiviral therapy : (London)</title><title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title><idno type="ISSN">1359-6535</idno><imprint><date when="2007">2007</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Antiviral therapy : (London)</title><title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title><idno type="ISSN">1359-6535</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral</term><term>Antiviral Agents (pharmacology)</term><term>Antiviral Agents (therapeutic use)</term><term>Cats</term><term>Cattle</term><term>Coronavirus</term><term>Dogs</term><term>Humans</term><term>Membrane Glycoproteins (chemistry)</term><term>Membrane Glycoproteins (drug effects)</term><term>Membrane Glycoproteins (metabolism)</term><term>Models, Molecular</term><term>Peptidyl-Dipeptidase A (drug effects)</term><term>Peptidyl-Dipeptidase A (metabolism)</term><term>Rabbits</term><term>Rats</term><term>Receptors, Virus (drug effects)</term><term>Receptors, Virus (metabolism)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Severe acute respiratory syndrome</term><term>Spike Glycoprotein, Coronavirus</term><term>Targeted therapy</term><term>Treatment</term><term>Viral Envelope Proteins (chemistry)</term><term>Viral Envelope Proteins (drug effects)</term><term>Viral Envelope Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Antiviraux (usage thérapeutique)</term><term>Bovins</term><term>Chats</term><term>Chiens</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires ()</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Humains</term><term>Lapins</term><term>Modèles moléculaires</term><term>Peptidyl-Dipeptidase A ()</term><term>Peptidyl-Dipeptidase A (métabolisme)</term><term>Protéines de l'enveloppe virale ()</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Rats</term><term>Récepteurs viraux ()</term><term>Récepteurs viraux (métabolisme)</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS ()</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Membrane Glycoproteins</term><term>Peptidyl-Dipeptidase A</term><term>Receptors, Virus</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Peptidyl-Dipeptidase A</term><term>Receptors, Virus</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Peptidyl-Dipeptidase A</term><term>Protéines de l'enveloppe virale</term><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Cats</term><term>Cattle</term><term>Dogs</term><term>Humans</term><term>Models, Molecular</term><term>Rabbits</term><term>Rats</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term><term>Bovins</term><term>Chats</term><term>Chiens</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires</term><term>Humains</term><term>Lapins</term><term>Modèles moléculaires</term><term>Peptidyl-Dipeptidase A</term><term>Protéines de l'enveloppe virale</term><term>Rats</term><term>Récepteurs viraux</term><term>Syndrome respiratoire aigu sévère</term><term>Coronavirus</term><term>Traitement</term><term>Antiviral</term><term>Thérapeutique ciblée</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>États-Unis</li></country><region><li>Berlin</li><li>Massachusetts</li></region><settlement><li>Berlin</li></settlement></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name></region><name sortKey="Choe, Hyeryun" sort="Choe, Hyeryun" uniqKey="Choe H" first="Hyeryun" last="Choe">Hyeryun Choe</name><name sortKey="Farzan, Michael" sort="Farzan, Michael" uniqKey="Farzan M" first="Michael" last="Farzan">Michael Farzan</name><name sortKey="Radoshitzky, Sheli R" sort="Radoshitzky, Sheli R" uniqKey="Radoshitzky S" first="Sheli R." last="Radoshitzky">Sheli R. Radoshitzky</name><name sortKey="Wenhui Li" sort="Wenhui Li" uniqKey="Wenhui Li" last="Wenhui Li">WENHUI LI</name></country><country name="Allemagne"><region name="Berlin"><name sortKey="Kuhn, Jens H" sort="Kuhn, Jens H" uniqKey="Kuhn J" first="Jens H." last="Kuhn">Jens H. Kuhn</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:07-0427335
|texte= Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies
}}
| This area was generated with Dilib version V0.6.33. |  |